Cargando…
Afatinib as first‐line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature
HER2 mutations are a rare group of driving genes that respond to HER2 targeted therapy, particularly afatinib. No more than 20 such cases have been reported, but afatinib was used after first‐line chemotherapy. We present the case of a never‐smoking female patient diagnosed with stage IV lung adenoc...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275816/ https://www.ncbi.nlm.nih.gov/pubmed/30379401 http://dx.doi.org/10.1111/1759-7714.12906 |